Quick Answer
Xilio Therapeutics, Inc. reported Total Assets of $154.69 million for fiscal year 2025.
Xilio Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $154.69M | +117.6% |
| 2024 | $71.08M | +16.7% |
| 2023 | $60.93M | -56.2% |
| 2022 | $139.16M | -36.2% |
| 2021 | $218.06M | +500.4% |
| 2020 | $36.32M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $133.69M | +79.1% | -0.1% |
| June 30, 2025 | $133.81M | +48.9% | +29.0% |
| March 31, 2025 | $103.72M | +25.6% | +45.9% |
| December 31, 2024 | $71.08M | +16.7% | -4.8% |
| September 30, 2024 | $74.66M | -4.1% | -16.9% |
| June 30, 2024 | $89.87M | -2.7% | +8.8% |
| March 31, 2024 | $82.61M | -25.9% | +35.6% |
| December 31, 2023 | $60.93M | -56.2% | -21.7% |
- Xilio Therapeutics, Inc. showed an increase of +117.6% in Total Assets compared to the prior fiscal year.
- Over the 2020–2025 period, Xilio Therapeutics, Inc.’s total assets has grown by 325.9% (from $36.32 million to $154.69 million).
- The most recent figure is from Xilio Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: